Who Is the Next "Baby Doe?" From Trisomy 21 to Trisomy 13 and 18 and Beyond

Pediatrics. 2020 Aug;146(Suppl 1):S9-S12. doi: 10.1542/peds.2020-0818D.

Abstract

The "Baby Doe" case of the early 1980s was marked by considerable controversy, primarily regarding the legal response of the federal government to the case at the time. In the decades that followed, the decision-making for children with trisomy 21, like Baby Doe, has been substantially reevaluated. The data, the assumptions about quality of life that were based on those data, and the ethical principles underpinning the decision-making in the Baby Doe case have all evolved significantly over time. The present strategies for decision-making for children with trisomy 13 and 18 appear to be following a similar pattern. The data, quality-of-life assumptions based on those data, and even the ethical principles underlying the decision-making for these children are currently being reexamined. Children with trisomy 13 and 18 are, in this regard, the next Baby Doe(s).

MeSH terms

  • Child Development
  • Clinical Decision-Making / ethics*
  • Down Syndrome / therapy*
  • Esophageal Atresia
  • Humans
  • Infant, Newborn
  • Kaplan-Meier Estimate
  • Parents
  • Quality of Life
  • Trisomy 13 Syndrome / mortality
  • Trisomy 13 Syndrome / therapy*
  • Trisomy 18 Syndrome / mortality
  • Trisomy 18 Syndrome / therapy*
  • Withholding Treatment / ethics
  • Withholding Treatment / legislation & jurisprudence